When a population of in vitro non-responders was identified among the patients with SLE, associations with a wide range of clinical parameters of the disease were sought. Table 1 shows the distribution of some of these (disease activity, serum anti-DNA binding, lymphopenia, and immunosuppressive therapy) among in vitro responders and nonresponders. Table 2 shows the statistical analysis of these associations. An impaired in vitro anti-influenza antibody response was significantly associated with a lymphocyte count of less than 1-3 x 10)/ml (p<0O00l) (Fig. 1 ) and higher serum anti-DNA antibodies (p<002) (Fig. 2) . There was no significant association with disease activity or immunosuppressive therapy. Eighteen patients and six controls received an influenza vaccination in both seasons of the study. The response to second time vaccination was significantly lower, both in vivo and in vitro. Although most of the in vitro non-responders had a greater than fourfold rise in serum antibody titre after vaccination, the peak serum response was significantly lower than in in vitro responders matched for age, treatment, and previous vaccination (p<0003). 
